title: From cancer genomics to precision oncology--tissue's still an issue.
abstract: Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation of personalized cancer medicine. However, genomics-based patient stratification across diverse tumor types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including the development and application of novel "rationally targeted" cancer therapies.
authors.affiliation: Calico Life Sciences, Suite 1200, 601 Gateway Boulevard, South San Francisco, CA 94080, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Cohen
authors.affiliation: Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: settleman.jeffrey@gene.com.
authors.forename: Jeff
authors.initials: J
authors.lastname: Settleman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D023281:Genomics; D006801:Humans; D009369:Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D057285:Precision Medicine
chemical_list: D000970:Antineoplastic Agents